Waters Parkerson & CO. LLC Has $21.87 Million Position in Zoetis Inc. (NYSE:ZTS)

Waters Parkerson & CO. LLC raised its holdings in Zoetis Inc. (NYSE:ZTS) by 2.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 126,177 shares of the company’s stock after buying an additional 3,270 shares during the quarter. Waters Parkerson & CO. LLC’s holdings in Zoetis were worth $21,874,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its position in Zoetis by 31.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after purchasing an additional 3,244,074 shares in the last quarter. Sarasin & Partners LLP grew its stake in shares of Zoetis by 546.3% in the 2nd quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock valued at $390,682,000 after purchasing an additional 1,904,899 shares during the period. Swedbank AB acquired a new position in shares of Zoetis in the 1st quarter worth approximately $210,815,000. Public Employees Retirement Association of Colorado bought a new position in shares of Zoetis during the 4th quarter worth approximately $242,757,000. Finally, CIBC Private Wealth Group LLC boosted its stake in Zoetis by 122.6% in the 4th quarter. CIBC Private Wealth Group LLC now owns 1,448,665 shares of the company’s stock valued at $285,923,000 after buying an additional 797,884 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 1.6 %

ZTS opened at $193.24 on Friday. The firm’s fifty day moving average is $184.42 and its two-hundred day moving average is $174.44. The firm has a market cap of $88.17 billion, a PE ratio of 37.23, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. During the same quarter last year, the business posted $1.41 EPS. The firm’s revenue was up 8.3% compared to the same quarter last year. Equities research analysts anticipate that Zoetis Inc. will post 5.84 EPS for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on ZTS. Stifel Nicolaus increased their price objective on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Piper Sandler lifted their price target on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Finally, BTIG Research upped their price objective on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $220.38.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.